Vaccines seem effective against Brazilian variant

9 March 2021

Lab research published in the New England Journal of Medicine suggests that Comirnaty, the coronavirus vaccine developed by BioNTech (Nasdaq: BNTX) and Pfizer (NYSE: PFE), could be effective against a Brazilian variant of concern.

The highly contagious P1 variant is spreading throughout Brazil, and has been detected in other countries, including the UK.

As well as being more transmissible than other forms of the virus, it is feared that the variant could be more resistant to either prior infection or inoculation with existing vaccines.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK